TY - JOUR
T1 - CA 19-9 in pancreatic cancer
AU - Ritts, R. E.
AU - Pitt, H. A.
PY - 1998
Y1 - 1998
N2 - CA 19-9 has achieved a defined role in the diagnosis, prognosis, and monitoring of patients with pancreatic cancer. For diagnosis, a reference value above 200 u/mL in a nonjaundiced patient with a confirming CT scan has a very high predictive value. For prognosis, a low preoperative value and a normal value after resection predict a good outcome. Similarly, CA 19-9 levels have been used successfully in monitoring the response to neoadjuvant therapy.
AB - CA 19-9 has achieved a defined role in the diagnosis, prognosis, and monitoring of patients with pancreatic cancer. For diagnosis, a reference value above 200 u/mL in a nonjaundiced patient with a confirming CT scan has a very high predictive value. For prognosis, a low preoperative value and a normal value after resection predict a good outcome. Similarly, CA 19-9 levels have been used successfully in monitoring the response to neoadjuvant therapy.
UR - http://www.scopus.com/inward/record.url?scp=0031886205&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031886205&partnerID=8YFLogxK
U2 - 10.1016/s1055-3207(18)30286-2
DO - 10.1016/s1055-3207(18)30286-2
M3 - Review article
C2 - 9443988
AN - SCOPUS:0031886205
VL - 7
SP - 93
EP - 101
JO - Surgical Oncology Clinics of North America
JF - Surgical Oncology Clinics of North America
SN - 1055-3207
IS - 1
ER -